SARS-CoV2 Infection Clinical Trial
Official title:
Reducing Respiratory Virus Transmission in Bangladeshi Classrooms
This study will test if affordable air cleaning devices (box fans with a filter attached and/or ultraviolet light lamps) installed in classrooms can reduce the number of viral respiratory illnesses schoolchildren experience.
This cluster-randomized controlled trial in Bangladesh schools will examine whether low-cost air filtration and/or human-safe ultraviolet germicidal light interventions can reduce the incidence of schoolchildren's respiratory viral infections. The main study objectives are: 1. Pilot and optimize an intervention to filter classroom air. 2. Pilot and optimize an intervention to treat classroom air with ultraviolet light. 3. Assess the separate and combined effect of air filtration and ultraviolet light on the incidence of polymerase chain reaction (PCR) confirmed illness from respiratory viruses. Methods: The study will take place in 60 government primary schools in Dhaka, Bangladesh. Within each enrolled school, 5 classrooms of students in grades 3, 4 and 5 will be randomly assigned to receive: 1. Box fans with a filter attachment. 2. 220 nanometer (nm) wavelength ultraviolet light air cleaner lamps. 3. Both the box fans with a filter and the 220 nm ultraviolet lamps. 4. No device: a control group that receives no additional device ("standard of care"). Two classrooms within each school will be assigned as controls. Why does this matter?: Clarifying the impact of low-cost practical solutions could support the adoption of these strategies that could reduce influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in schools in order to reduce the burden of respiratory illness in these communities. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Recruiting |
NCT05311410 -
Viral Kinetics of SARS-CoV-2 in Patients With COVID-19 in the Intensive Care Unit Undergoing Dental Procedures
|
N/A | |
Active, not recruiting |
NCT05073718 -
SARS-CoV-2 and Acetylsalicylic Acid (SARA)
|
Phase 3 | |
Completed |
NCT05055492 -
The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions
|
N/A | |
Completed |
NCT05055505 -
The School SPIT Study - Elementary Schools in Low COVID-19 Incidence Regions
|
N/A | |
Completed |
NCT05060510 -
The School SPIT Study - COVID-19 Testing in Secondary Schools
|
N/A | |
Completed |
NCT05054218 -
COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
|
||
Completed |
NCT05449392 -
Topical Antibacterial Agents for Prevention of COVID-19
|
Phase 1 | |
Completed |
NCT05076253 -
Efficacy of Ivermectin in COVID-19
|
Phase 1/Phase 2 | |
Recruiting |
NCT05172024 -
Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
|
||
Terminated |
NCT05593770 -
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
|
Phase 2/Phase 3 | |
Completed |
NCT05030974 -
RECOVAC Repeated Vaccination Study
|
Phase 4 | |
Withdrawn |
NCT05067946 -
Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05013034 -
Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients
|
Phase 2 | |
Withdrawn |
NCT05393999 -
SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations
|
Phase 2 | |
Recruiting |
NCT05047783 -
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
|
Phase 2 | |
Not yet recruiting |
NCT05116657 -
Obstructive Sleep Apnoea Post Covid 19: Role of the Upper Airway Microbiome
|
||
Recruiting |
NCT04590222 -
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19
|
||
Completed |
NCT04551911 -
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
|
Phase 2 | |
Completed |
NCT04953039 -
Use of Saliva for COVID-19 Diagnosis
|